The COVID-19 vaccine being developed in China on Experimental basis showed safety signs in the first stage of clinical trial, researchers said on Wednesday.
According to reports, the trial of the vaccine was done by the Institute of Medical Biology under the Chinese Academy of Medical Sciences
As per the statistics,191 healthy participants aged between 18 and 59, were administered the vaccine in the phase 1 trial, which have showed no severe adverse reactions, researchers stated.
Meanwhile, the most common adverse reactions reported by the trial participants were only the mild pain, slight fatigue, redness, itching and swelling at the injection site.
“All the data obtained in this trial support the safety and immunogenicity of this inactivated vaccine and are encouraging with regard to further studies of its efficacy in the future,” said the researchers.
“The candidate also induced immune response”, the researchers added.
The country has vaccinated hundreds of thousands of workers and other groups posed at high risk with other vaccines, even as clinical trials had not been fully completed, raising safety concerns among experts.
It is worth mention here that China has at least four experimental vaccines in the final works of clinical trials.